Singapore, Oct. 15 -- The Health Sciences Authority (HSA) in Singapore has announced three initiatives to help promising healthcare innovations reach patients sooner: (i) collaboration with the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) through the Regulatory Innovation Corridor on regulatory considerations for breakthrough therapies that use Artificial Intelligence (AI) in drug development and clinical trials; (ii) a common entry point for clinical research and regulatory engagement in Singapore; and (iii) a HSA-Agency for Care Effectiveness (ACE) Priority Track that will allow selected health products to undergo regulatory evaluation and health technology assessment concurrently.

The initiatives could h...